Semaglutide keeps expanding its territory, nervously
Two semaglutide-adjacent threads ran today. One covered a study linking semaglutide to lower predicted dementia risk, generating cautious excitement alongside sharp skepticism: the study used a proteomics-based risk signature, which commenters called 'clinically meaningless.' A second thread covered AI in drug discovery more broadly, with the community noting that the field is still early and people need to think harder about why they are running the experiments they are running.
The pattern: semaglutide (Ozempic, Wegovy) keeps showing up in studies with positive signals across metabolic disease, cardiovascular risk, and now neurodegeneration. The scientific community is excited but also increasingly aware that Novo Nordisk has a financial interest in generating this data, and that the competitor tirzepatide is gaining ground.
This is becoming a recurring signal on HN: GLP-1 drugs as a platform, not just a weight-loss product. The debate is whether the downstream effects are real or an artifact of weight loss itself.
So what?
For founders in digital health, chronic disease management, or drug discovery tooling, GLP-1 drugs are reshaping the patient population and the research landscape simultaneously. Companies building for obesity, diabetes, cardiovascular, or dementia patients need to model a world where a significant fraction of that population is on semaglutide or a successor. That changes baseline assumptions about disease progression and treatment adherence.